The weight loss on GLP-1 therapy is real and often significant — 15 to 22% of body weight over a year is now routine with tirzepatide. What doesn't get discussed clearly enough is what happens when the drug stops: most of that weight comes back. Not all of it, not immediately, but enough, and fast enough, that the decision to stop deserves more deliberate preparation than most patients receive.
This isn't a willpower problem. It's pharmacology. The drug changed the inputs to your appetite and satiety system; removing the drug restores the original signals. Understanding that mechanism is what makes a difference between being blindsided by regain and having a plan.
What the data says
The SURMOUNT-4 trial gives the clearest picture. Participants lost an average of 21% of their body weight on tirzepatide over 36 weeks. They were then randomized to continue tirzepatide or switch to placebo — meaning they stopped the drug while believing they might still be on it.
Within the follow-up period, the placebo group regained an average of about 14% of their original starting weight. Not 14% of the weight they lost — 14% of their total body weight. When you do that math, you're talking about regaining two-thirds to three-quarters of the loss.
That's the ~70% regain figure you'll see cited: broadly, most people who stop a GLP-1 regain most of what they lost, in a matter of months, not years. The timeline is fast because hunger returns fast. Within weeks of stopping, patients describe the return of "food noise" — the persistent background craving that the drug had been suppressing — and appetite volumes that feel similar to what they were before treatment.
The SURMOUNT-MAINTAIN trial adds important nuance: people who dropped from a maximum tolerated dose of tirzepatide to 5mg (instead of stopping entirely) maintained meaningfully better outcomes — around 16.5% total weight loss versus 10% for the placebo group. The dose reduction still resulted in some regain, but substantially less than full discontinuation. The therapeutic effect, even at a reduced dose, continued to blunt the biological pressure to regain.
Note(The average conceals the individual range)
The "regained two-thirds" headline is a population average. In SURMOUNT-4, roughly 17% of people who stopped tirzepatide maintained most of the weight they had lost without the drug. Another 25% regained about a quarter of their losses. The rest regained substantially more. The patients who regained the least tended to be the same ones who had responded best initially — suggesting that some people have a less severe underlying obesity biology to begin with.
Why regain happens
GLP-1 therapy isn't behavioral retraining. The drug doesn't teach you to want less food — it pharmacologically suppresses the hormonal signals that drive appetite. GLP-1 and GIP receptors in the hypothalamus, the brain's hunger-regulation center, are activated by the medication and reduce the drive to seek and consume food.
When the drug leaves the system, those receptors go back to their baseline activity. The hunger signaling that existed before treatment returns. This isn't subtle — it's the same set of signals that have been there since the patient's obesity developed, and the body defends the weight set point it established before treatment began.
The mechanism is called adaptive thermogenesis: the body resists weight loss by reducing resting metabolic rate, increasing hunger hormones (ghrelin goes up, leptin goes down), and suppressing satiety signaling. These adaptations persist after weight loss, even when the drug is gone. The brain is actively pulling back toward the previous weight, and without the pharmacological override the drug provided, most people feel and eventually respond to that pull.
This is the same biology that makes weight regain so universal after caloric restriction diets. GLP-1 drugs suppress these signals more effectively than behavioral approaches — but only while active. Stopping the drug is not like stopping a blood pressure medication where the baseline returns slowly. The hunger signals return within days to weeks, and without a counter-intervention in place, behavior follows.
Intuition(The drug was fighting your biology, not teaching it)
A useful way to think about it: GLP-1 therapy is like pharmacologically lowering the thermostat on your appetite. The thermostat itself — the biological set point shaped by genetics, adipose tissue mass, and hormonal feedback loops — hasn't changed. When the drug stops, the thermostat returns to where it was set. The only things that actually reset the set point over time are sustained changes in body composition (particularly muscle mass) and, in some people, long-term metabolic remodeling that isn't well understood yet. Neither of those is guaranteed to happen in the time someone is on the drug.
The maintenance dose option
The most important clinical option that patients often don't know exists: a lower dose that sustains results with fewer side effects and lower cost.
The current published evidence supports this approach. In SURMOUNT-MAINTAIN, 5mg tirzepatide — the entry-level dose — maintained substantially more weight loss than stopping entirely. Many experienced clinicians have found patients doing well on even lower and less-frequent dosing: every-10-day injections, microdoses of 2.5mg, or in some cases monthly injections that keep food noise under sufficient control to prevent regain.
The goal isn't always maximum weight loss. The goal is the minimum effective dose — the dose at which the patient maintains their clinical benefits without unnecessary cost, side effects, or injection burden. For some patients, that's 15mg tirzepatide or 2.4mg semaglutide indefinitely. For others, it's 5mg tirzepatide every 10 days. The only way to find it is to titrate down systematically while monitoring weight and symptom return.
Staying on the medication indefinitely is also a legitimate clinical choice. These drugs aren't treatments for a time-limited condition — obesity is chronic and relapsing. The drugs have now demonstrated cardiovascular mortality benefits independent of weight loss. A patient who can tolerate the drug and has access to it has a reasonable case for staying on it long-term, at whatever dose maintains the effect, for the same reason that a hypertensive patient stays on an antihypertensive indefinitely.
What needs to be in place before stopping
If stopping is the goal — due to cost, side effects, insurance, pregnancy, or personal preference — the outcomes are meaningfully better when certain habits are consolidated before discontinuation, not attempted afterward.
Resistance training baseline. The patients who do best after stopping GLP-1s are the ones who built muscle during the treatment period. Muscle is metabolically expensive and keeps resting metabolic rate from declining as sharply during weight maintenance. Two to three structured sessions per week of progressive resistance training, established and habitual before stopping, is the single most protective intervention available.
Protein habits. High protein intake (targeting 1.2–1.6g per kg of target body weight) helps preserve lean mass and provides more satiety per calorie than either fat or carbohydrate. Eating patterns built around protein as the anchor — rather than the drug's appetite suppression — continue to function when the drug leaves.
An understanding of hunger signals. Patients who are aware that food noise will return, and who have a plan for it rather than being surprised by it, tend to do better. This sounds obvious, but many patients assume the drug changed something permanently. Knowing that the hunger is a predictable pharmacological effect — not a personal failure — helps keep behavior in check during the early weeks after stopping.
Not using the drug as a crutch for every food decision. The patients who struggle most after stopping are those who made zero changes to their food environment and food choices during treatment, relying entirely on appetite suppression to do the work. The drug made those decisions unnecessary. Without it, nothing protects against the original eating patterns returning.
Weight loss plateaus during therapy
Plateaus during active treatment are different from stopping entirely and deserve their own explanation because they're often misinterpreted.
Most people plateau somewhere during GLP-1 therapy. This is expected. Early in treatment, weight loss is rapid because the deficit is large — appetite is suppressed before the body adapts. Over time, metabolic adaptation occurs: resting metabolic rate decreases as body mass decreases, and the original aggressive deficit narrows. This is not the drug "wearing off." It's the body arriving at a new equilibrium.
A plateau after several months of treatment on a stable dose usually means one of three things:
- The body has adapted to the current deficit and is no longer in a meaningful one
- Food intake has crept up as appetite suppression habituates (this happens more than people realize)
- The current dose is at its ceiling effect for that patient
The plateau is expected if it follows a period of substantial weight loss and the patient has been on the same dose for months. It signals a decision point: accept current weight as maintenance, increase dose if clinically warranted and possible, or restructure food patterns to reopen a deficit. Spontaneous plateaus within the first 12 weeks on a stable dose are a signal something else is happening and warrant a clinical conversation.
If you have to stop
A tapered approach is generally preferred over abrupt discontinuation, though the pharmacokinetics of weekly-injected semaglutide and tirzepatide mean the taper is somewhat built in — these drugs have half-lives of 5–7 days and take weeks to fully clear. "Cold stopping" a weekly injection doesn't produce an immediate rebound. What patients experience over the following 2–4 weeks is a progressive return of appetite, not an immediate reversal.
What to expect in the weeks after stopping:
- Weeks 1–2: Minimal change in most patients. The drug is still clearing. Some report noticing food noise beginning to return by the end of week 2.
- Weeks 3–4: Appetite returns more substantially. Hunger between meals, desire for larger portions, and cravings for hyperpalatable foods re-emerge. This is the period where without preparation, eating patterns revert.
- Weeks 5–8: The actual weight regain begins in most patients who haven't made behavioral changes. The scale tells the story.
To slow regain: maintain or increase resistance training frequency (this is the moment it matters most), prioritize protein at every meal, reduce exposure to hyperpalatable food environments, and set a weight trigger — a specific number at which you contact your provider to restart medication or discuss alternatives. Proactive monitoring and early intervention are far more effective than waiting until substantial regain has occurred.
User Sentiment
The community consensus on stopping has shifted noticeably in the last two years. Early adopters went off the medication expecting their changed eating habits to carry them — and many came back several months later having regained a significant portion of their weight. That collective experience made the forums far more realistic about what stopping means.
Example(What the community says)
The threads in r/Mounjaro and r/Semaglutide about stopping follow a consistent arc: initial optimism ("I've built good habits, I think I'll be fine"), followed several weeks later by a post describing food noise returning and confusion about why they're suddenly hungry all the time. The most-upvoted replies are now experienced voices explaining the biology — that appetite hormones returning is expected, not a sign something is wrong. The community has largely landed on "stay on the lowest dose you can afford" as the practical consensus, with discontinuation treated as a last resort rather than a success condition.
Who It's For
This post is for anyone who is considering stopping a GLP-1 drug, has been asked to stop for insurance or clinical reasons, or has been on the drug long enough to start thinking about what comes after. It's also for people who plateaued and are assuming the drug has "stopped working."
The decision to stop, maintain on a lower dose, or continue at full dose is a clinical one that depends on individual disease severity, cost, tolerance, and goals. What this post argues is that the decision should be made with a realistic understanding of what stopping usually produces — and with a plan in place before the last injection, not after.
Summary(The short version)
Stopping a GLP-1 drug reverses most of its appetite-suppressing effects. The body's hunger signaling, which the drug was pharmacologically overriding, returns — and with it, the biological pressure to regain weight. The SURMOUNT-4 trial showed that on average, people who stopped tirzepatide after achieving significant weight loss regained about two-thirds of it. The minority who maintained their loss either had less severe underlying obesity biology or had built durable lifestyle habits during treatment — particularly resistance training and protein-centered eating. The maintenance dose option (a lower, less-frequent injection) is clinically supported and underutilized. If stopping is necessary, the first two to four weeks after the last dose are the highest-risk period; a plan should be in place before that point, not invented in response to regain.